just curious why you always post what's already posted at...

First 6 Last

Share
Profile

Follow
thorndog

1,025 Posts.

192

30/05/22

10:06

Post #: 61696255
Share

Originally posted by moosey: ↑

Level 2, 66 Hunter Street

Sydney NSW 2000

Tel: (61-2) 9300 3344

Fax: (61-2) 9221 6333

E-mail: [email protected]

Website: www.biotron.com.au

30 May 2022

The Manager Companies

ASX Limited

20 Bridge Street

SYDNEY NSW 2000 (2 pages by email)

Dear Madam

POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM

The Directors are pleased to advise that Biotron Limited (‘Biotron’ or ‘the Company’ has received

guidance from the U.S. Food and Drug Administrations (‘FDA’ for development of its lead antiviral

drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults.

The FDA’s guidance was received in written respons e to Biotron’s pre-IND briefing package and

request in March 2022, which include d an overview of preclinical a nd (HIV) clinical development,

and specific questions relating to re gulatory requirements for progressi on to filing an investigational

new drug (‘IND’ application for the COVID-19 indication.

Biotron sought guidance on the design of a proposed Phase 2 clinical trial in recently diagnosed

COVID-19 infected individuals and assurance that the preclinical data package and manufacturing

processes were sufficient to support this next stage of clinical development.

Biotron’s Managing Director, Dr Michelle Miller, said:

“The FDA responses were constructive, highly informative, and provide direction in the design of the

proposed Phase 2 clinical trial. The recommenda tions for a small, placebo-controlled, proof-of-

concept, dose-finding study, with agreed end points, in line with studies for other respiratory diseases,

including influenza, are very welcome. This design is de-risking and will provide the Company with

important time and resource savings.

The feedback on the existing sup porting non-clinical studies and the manufacturing processes,

specification and composition of the drug product was positive.

The design of regulatory-quality clinical studies for SARS-CoV-2 therapeutic advancement during this

currently evolving disease and treatment landscape, re quires careful considerat ion. We now have a

clear directive for the design of a Phase 2 study. This guidance will inform the on-going development

of BIT225 and subsequent next-generation follow-on drugs in Biotron’s portfolio.

The FDA responses indicate that we are on the right path to the clinic. Our confidence levels for this

new class of anti-SARS-Cov-2 drug remain high.”

Expand

just curious why you always post what's already posted at the top of announcements?

BIT Price at posting: 10.8¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

LIS

Li-S Energy the latest microcap to pivot to US defence market

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

ASX Market Close: Why are we red today? Because US CPI's at 3%

LDX

Lumos Diagnostics surges 140% on major US contract deal

LU7

Lithium Universe targets silver boom with breakthrough solar recycling tech

There are more pages in this discussion • 113 more messages in this thread...

First 6 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.2¢		Change 0.000(0.00%)		Mkt cap ! $2.654M

Open	High	Low	Value	Volume
0.2¢	0.2¢	0.2¢	$90	45.00K

Buyers (Bids)

No.	Vol.	Price($)
47	30038263	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	16274992	22

View Market Depth

No.	Vol.	Price($)
47	30038263	0.002
30	82741500	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	14500871	21
0.004	17270968	18
0.005	6690600	5
0.006	1200000	2
0.007	484188	1

Last trade - 12.52pm 16/07/2025 (20 minute delay)

BIT (ASX) Chart

just curious why you always post what's already posted at...

Li-S Energy the latest microcap to pivot to US defence market

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

ASX Market Close: Why are we red today? Because US CPI's at 3%

Lumos Diagnostics surges 140% on major US contract deal

Lithium Universe targets silver boom with breakthrough solar recycling tech

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

just curious why you always post what&apos;s already posted at...

Top Stories

Li-S Energy the latest microcap to pivot to US defence market

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

ASX Market Close: Why are we red today? Because US CPI's at 3%

Lumos Diagnostics surges 140% on major US contract deal

Lithium Universe targets silver boom with breakthrough solar recycling tech

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

just curious why you always post what's already posted at...